study a composite ma for the overall usefulness of the treatment was con u, the objective and the subjective Power ON Tzung incorporated the advantages and disadvantages. After the benefits of comprehensive treatment, treatment with oxaliplatin showed clear evidence of benefit overall. Cisplatin showed a significant h Here rate the patient’s response JTP-74057 MEK inhibitor and a L Ngere time to progression, a combination of 5-FU, doxorubicin and mitomycin C or fluorouracil regime and FP is now the standard for first line palliative chemotherapy in Korea. Patients with AGC were treated with systemic chemotherapy, and several randomized studies have shown a slight improvement in Lebensqualit t and the survival benefit of chemotherapy versus BSC demonstrated.
However, when patients are undergoing chemotherapy may progress to develop the disease, established r788 1025687-58-4 in every other line scheme can be offered, in spite of what is h INDICATIVE clinical scenario. However, most patients in Korea are candidates for second-line therapy after failing to address the treatment of choice, as advanced or recurrent gastric cancer is as h Matogene / lymphatic metastasis or peritoneal seeding very slowly. In addition to the patients with good performance status second-line chemotherapy. Therefore, many studies, the second-line chemotherapy in advanced gastric adenocarcinoma in Korea have been investigated. However, there were no surveys to second-line chemotherapy, in which the first-line chemotherapy of AGC has taken into consideration. We reviewed reports of clinical trials in Korea, where FP standard chemotherapy has been primarily palliative.
The purpose of this test was to evaluate the efficacy and safety of second-line chemotherapy with inoperable or recurrent gastric cancer. In particular, we focused on the RR, the possibility of overall survival and the reps. We then have the options for second-line treatment of AGC on the basis of evidence available in Korea. Materials and Methods We conducted a literature database PubMed search to December 2010 electronic ver is the phase II / III clinical trials in Korea Published in full and H He in the scientific literature. Inclusion criteria were evidence that patients had histologically or recurrent primary R proven inoperable adenocarcinoma of the stomach and was previously with simple regimen of palliative chemotherapy were treated with response assessed by the WHO and RECIST criteria.
The Posts GE were on immunotherapy and other cytotoxic agents or not, the evaluation of the response of various tumor types of the same scheme is not considered. Including testing, Lich chemona ı ¨ ve patients were excluded. However, studies on salvage chemotherapy were included, but only if the number of patients receiving chemotherapy, second-line was more than ten years old. No RESTRICTIONS Language Website will have been used. Most studies of second line chemotherapy in AGC has been Japan, Korea and Italy, where the practice to provide second-line treatment for patients with AGC carried out as usual. The first line of chemotherapy in these countries too are used are different. No journal articles on second-line chemotherapy as front-line chemotherapy of AGC was. We selected reports of clinical studies in Korea. Conclusions In 20 studies of patients with stage II histologically identified with p